Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial - Top-Institutions - MDSpire

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

  • By

  • M Tobiasson

  • I Dybedahl

  • M S Holm

  • M Karimi

  • L Brandefors

  • H Garelius

  • M Grövdal

  • I Högh-Dufva

  • K Grønbæk

  • M Jansson

  • C Marcher

  • L Nilsson

  • A O Kittang

  • A Porwit

  • L Saft

  • L Möllgård

  • E Hellström-Lindberg

  • March 7, 2014

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Stem Cell Transplantation

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Genomic Medicine

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Clinical Research

  • #4

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, N/A

    Key Differentiators

    • Hematology
    • Clinical Research
    • Molecular Medicine

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Clinical Trials

Original Source(s)

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

  • by M Tobiasson, I Dybedahl, M S Holm, M Karimi, L Brandefors, H Garelius, M Grövdal, I Högh-Dufva, K Grønbæk, M Jansson, C Marcher, L Nilsson, A O Kittang, A Porwit, L Saft, L Möllgård, E Hellström-Lindberg

  • March 7, 2014

Related Content

Clinical Findings in Migrants With Asymptomatic Plasmodium Infections

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

  • February 26, 2025

  • 1 min
VEXAS Syndrome for the laboratory physician: a case report